miR‐181a induces sorafenib resistance of hepatocellular carinoma cells through downregulation of RASSF1 expression

Sorafenib, a multi‐kinase inhibitor, is the only standard clinical drug for patients with advanced hepatocellular carcinoma (HCC); however, development of sorafenib resistance in HCC often prevents its long‐term efficacy. Therefore, novel targets and strategies are urgently needed to improve the ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Azumi, Junya, Tsubota, Toshiaki, Sakabe, Tomohiko, Shiota, Goshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021022/
https://www.ncbi.nlm.nih.gov/pubmed/27384977
http://dx.doi.org/10.1111/cas.13006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021022/
https://www.ncbi.nlm.nih.gov/pubmed/27384977
http://dx.doi.org/10.1111/cas.13006

Ejemplares similares